Agios Pharmaceuticals Shares Plunge 26.8% Following Novo Nordisk Drug Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy AGIO?
Source: Fool
- Stock Price Plunge: Agios Pharmaceuticals' shares fell by 26.8% over the week, reflecting a decline in market confidence regarding its rival drug mitapivat, particularly after Novo Nordisk announced positive clinical results for its drug etavopivat, raising investor concerns about Agios' future market potential.
- Competitive Drug Performance: Novo Nordisk's etavopivat met its primary endpoints in Phase 3 trials, significantly improving hemoglobin response and reducing vaso-occlusive crises, while Agios' mitapivat achieved its hemoglobin response endpoint but failed to outperform placebo in annualized rates of pain crises, indicating a lack of competitive edge.
- Regulatory Path Uncertainty: Agios is currently working with the FDA to align on a mitapivat trial necessary for submission under an accelerated approval process, but the latest news from Novo introduces uncertainty regarding mitapivat's market potential and regulatory pathway, potentially impacting future sales forecasts.
- Future R&D Opportunities: Despite these challenges, Agios may have another PK activator, tebapivat, set to report results in the second half of 2026, which could present new growth opportunities for the company, warranting close attention from investors regarding its progress.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AGIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AGIO
Wall Street analysts forecast AGIO stock price to rise
9 Analyst Rating
6 Buy
3 Hold
0 Sell
Moderate Buy
Current: 25.740
Low
25.00
Averages
36.14
High
62.00
Current: 25.740
Low
25.00
Averages
36.14
High
62.00
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Agios Pharmaceuticals Shares Plunge 26.8% Following Novo Nordisk Drug Results
- Stock Price Plunge: Agios Pharmaceuticals' shares fell by 26.8% over the week, reflecting a decline in market confidence regarding its rival drug mitapivat, particularly after Novo Nordisk announced positive clinical results for its drug etavopivat, raising investor concerns about Agios' future market potential.
- Competitive Drug Performance: Novo Nordisk's etavopivat met its primary endpoints in Phase 3 trials, significantly improving hemoglobin response and reducing vaso-occlusive crises, while Agios' mitapivat achieved its hemoglobin response endpoint but failed to outperform placebo in annualized rates of pain crises, indicating a lack of competitive edge.
- Regulatory Path Uncertainty: Agios is currently working with the FDA to align on a mitapivat trial necessary for submission under an accelerated approval process, but the latest news from Novo introduces uncertainty regarding mitapivat's market potential and regulatory pathway, potentially impacting future sales forecasts.
- Future R&D Opportunities: Despite these challenges, Agios may have another PK activator, tebapivat, set to report results in the second half of 2026, which could present new growth opportunities for the company, warranting close attention from investors regarding its progress.
See More
AGIOS PHARMACEUTICALS INC: H.C. Wainwright Lowers Price Target from $65 to $50
- Price Adjustment: The price of H.C. Wainwright's target for A.G.I.O. Pharmaceuticals has been reduced from $65 to $50.
- Market Impact: This price cut may reflect changes in market conditions or company performance expectations.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
Agios Pharmaceuticals Shares Plunge 26.8% Following Novo Nordisk Drug Results
- Stock Price Plunge: Agios Pharmaceuticals' shares fell by 26.8% over the week, reflecting a decline in market confidence regarding its rival drug mitapivat, particularly after Novo Nordisk announced positive clinical results for its drug etavopivat, raising investor concerns about Agios' future market potential.
- Competitive Drug Performance: Novo Nordisk's etavopivat met its primary endpoints in Phase 3 trials, significantly improving hemoglobin response and reducing vaso-occlusive crises, while Agios' mitapivat achieved its hemoglobin response endpoint but failed to outperform placebo in annualized rates of pain crises, indicating a lack of competitive edge.
- Regulatory Path Uncertainty: Agios is currently working with the FDA to align on a mitapivat trial necessary for submission under an accelerated approval process, but the latest news from Novo introduces uncertainty regarding mitapivat's market potential and regulatory pathway, potentially impacting future sales forecasts.
- Future R&D Opportunities: Despite these challenges, Agios may have another PK activator, tebapivat, set to report results in the second half of 2026, which could present new growth opportunities for the company, warranting close attention from investors regarding its progress.
See More
AGIOS PHARMACEUTICALS INC: H.C. Wainwright Lowers Price Target from $65 to $50
- Price Adjustment: The price of H.C. Wainwright's target for A.G.I.O. Pharmaceuticals has been reduced from $65 to $50.
- Market Impact: This price cut may reflect changes in market conditions or company performance expectations.
See More
Novo's Successful Trial Impacts Agios Stock Performance
- Novo Trial Success: Novo's Phase 3 trial of Etavopivat for sickle cell disease met both primary endpoints, significantly reducing painful vaso-occlusive crises and delaying the median time to first crisis by nearly four months, showcasing its competitive edge in the treatment landscape.
- Agios Stock Decline: Following Novo's positive trial results, Agios Pharmaceuticals (AGIO) shares plummeted over 25% on Monday, snapping a five-day winning streak, raising concerns about its future competitiveness with AGIO trading around $27.
- Competitive Pressure: Truist analyst noted that Novo's favorable data could exert pressure on Agios' stock, limiting its ability to rebound towards $40, although he remains optimistic about Mitapivat's potential in treating sickle cell disease.
- Investor Sentiment Shift: Despite the sharp decline in AGIO shares, retail investor sentiment shifted to 'bullish', indicating confidence in AGIO as a long-term investment, reflecting the market's complex view on its future performance.
See More
Agios Pharmaceuticals Shares Plunge 23% Amid Competitive Drug News
- Significant Stock Drop: Agios Pharmaceuticals' shares plummeted by 23% today, falling from $26.99 to $20.84, reflecting market concerns over its earnings potential amid competitive pressures from rival drugs.
- Competitive Drug Success: Novo Nordisk's etavopivat successfully met both co-primary endpoints in the HIBISCUS phase 3 trial, demonstrating significant efficacy, which poses a direct threat to Agios' mitapavit and its market position.
- Trial Results Comparison: While Agios' mitapavit showed improvements in hemoglobin levels for sickle cell disease patients, it failed to achieve statistically significant results in reducing pain crisis rates, further complicating its market outlook.
- Extended FDA Approval Path: Agios is working with the FDA to align on the confirmatory clinical trial required for submission, but compared to Novo's advancements, its path to approval appears longer and more uncertain, potentially undermining investor confidence.
See More
Agios Pharmaceuticals Under Investigation Following Phase 3 Trial Results, Stock Plummets
- Investigation Launched: Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals, Inc. regarding potential violations of federal securities laws, indicating serious concerns about the company's compliance practices.
- Clinical Trial Results: On November 19, 2025, Agios reported that its RISE UP Phase 3 trial met one primary endpoint but failed to show statistically significant improvement in annualized pain crises, highlighting limitations in treatment efficacy.
- Stock Price Reaction: Following the trial results, Agios' stock plummeted by $22.33 to open at $23.16, reflecting a significant decline in market confidence regarding the company's future prospects, which may impact its ability to raise capital.
- Investor Impact: The investigation and stock drop could erode investor trust in Agios, further affecting its market performance and shareholder value, underscoring the company's inadequate risk management in clinical development.
See More
Health Care Stocks Rise 2% Boosting Market
- Strong Performance in Health Care: Late Tuesday afternoon, the NYSE Health Care Index rose by 2%, indicating a rebound in investor confidence towards the health sector, likely driven by an overall improvement in market sentiment.
- Signs of Market Recovery: The rise in health care stocks reflects optimistic expectations for economic recovery, particularly post-pandemic, as demand for health services continues to grow, potentially boosting the performance of related companies.
- Increased Investor Attention: With the improved performance of the health care sector, investors may reassess their portfolios and increase allocations to health stocks, thereby driving further growth and stability in the industry.
- Optimistic Industry Outlook: The strong performance in the health sector could attract more capital inflows, especially in the fields of innovative drugs and medical technologies, which are expected to provide momentum for future growth.
See More
